Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal antibody variable regions
The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin V L domain linked to an immunoglobulin V H domain in which the V L domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the V H domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1 is GYSFTGYNMN VHCDR2 is NIDPYYGGTTYNQKFKG VHCDR3 is EVDY VLCDR1 is RASKSVSTSTSGYSYMH VLCDR2 is LVSNLES VLCDR3 is QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.
1. An antigen binding fragment of an antibody, wherein the antigen binding fragment specifically binds to a peptide comprising the amino acid sequence of EDGIKRIQDD (SEQ ID NO:1) and comprises an immunoglobulin V L domain linked to an immunoglobulin V H domain, wherein the V L domain comprises Complementary Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and the V H domain comprises Complementary Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each consisting of the amino acid sequence as follows
VHCDR1 is GYSFTGYNMN;
(SEQ ID NO: 2)
VHCDR2 is NIDPYYGGTTYNQKFKG;
(SEQ ID NO: 3)
VHCDR3 is EVDY;
(SEQ ID NO: 4)
VLCDR1 is RASKSVSTSGYSYMH;
(SEQ ID NO: 5)
VLCDR2 is LVSNLES;
(SEQ ID NO: 6)
VLCDR3 is QHIRELTRSEG
(SEQ ID NO: 7).
2. The antigen binding fragment as claimed in claim 1 comprising a polypeptide comprising the amino acid sequence of SEQ ID.
3. A composition comprising the antigen binding fragment as claimed in claim 1 and angiotensin-II protein.
4. A pharmaceutical composition comprising the antigen binding fragment as claimed in claim 1 .
5. A pharmaceutical composition comprising the antigen binding fragment as claimed in claim 1 and angiotensin-II protein.